Answers are grounded in this paper and cite their sources.
Chronic stress-induced dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is a crucial early risk factor that triggers brain energy metabolism disorders to accelerate the onset and progression of Alzheimer’s disease (AD). Herein, an amphiphilic precursor conjugate of ginsenoside Rc (Rc) covalently linked with a reactive oxygen species-sensitive thioketo bond is constructed to form stimuli-responsive prodrug assemblies, which are further modified with the TGN-Tet1 dual-ligand fusion peptide TPL to obtain a chronic stress-triggerable programmed nanoprodrug (TLRN). Following TPL-mediated blood-brain barrier penetration and neuronal preferential targeting, nanoprodrugs specifically disintegrate to selectively release active Rc in the chronic stress-induced excessive reactive oxygen species (ROS) microenvironment. Benefiting from the restoration of HPA axis homeostasis by normalizing glucocorticoid receptor nuclear translocation, TLRN treatment exhibits multifaceted rectification of cerebral metabolic abnormalities, including enhancing glucose uptake, promoting oxidative phosphorylation, and mitigating mitochondrial dysfunction. In young amyloid precursor protein/presenilin 1 (APP/PS1) transgenic mouse models exposed to chronic stress, this intervention can alleviate brain energy deprivation and amyloid-β (Aβ) accumulation, ultimately rescuing depressive-like behaviors and cognitive deficits, offering a promising approach for early prevention and flexible management of AD at high risk of chronic stress.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: